Introduction {#tca13023-sec-0001}
============

Lung cancer is one of the most aggressive malignant tumors and the most common cause of cancer‐related death in the world.[1](#tca13023-bib-0001){ref-type="ref"} The identification of molecular events underlying pathogenesis has improved the clinical treatment and outcome of lung cancers.[2](#tca13023-bib-0002){ref-type="ref"}, [3](#tca13023-bib-0003){ref-type="ref"}, [4](#tca13023-bib-0004){ref-type="ref"}, [5](#tca13023-bib-0005){ref-type="ref"} Among all of the new treatment strategies, immunotherapy is one of the most promising. Studies have proven that agents targeting immune checkpoint receptors (ICIs) are effective and well tolerated as second‐line treatment in non‐small cell lung cancer (NSCLC) with PD‐L1 overexpression or without.[6](#tca13023-bib-0006){ref-type="ref"}, [7](#tca13023-bib-0007){ref-type="ref"} However, like all antitumor treatments, the effect of immunotherapy is largely limited by its drug resistance. Few studies have reported the resistance mechanism to ICIs. Herein, we present a case of a patient who developed resistance to nivolumab. Next generation sequencing (NGS) was used to investigate the drug resistance mechanism and therefore provide further treatment strategies.

Case presentation {#tca13023-sec-0002}
-----------------

A 48‐year‐old smoking man came to the hospital complaining of three months of back pain. Computed tomography (CT) showed a tumor in the right upper lobe of the lung and pleural disseminations; whole‐body bone scintigraphy showed bone metastasis of thoracic vertebra. The right upper lobe of the lung was resected by video‐assisted thoracic surgery for diagnosis. Histological examination showed adenosquamous carcinoma with CK, CK7, and CK5/6 expression on tumor cells (Fig [1](#tca13023-fig-0001){ref-type="fig"}b). A large NSG panel (Burning Rock, Guang Zhou, China), including 168 somatic driver genes related to lung cancer (supplementary material 1) was taken of both tumor tissue and plasma, and mutations in the tested genes were not detected (Fig [1](#tca13023-fig-0001){ref-type="fig"}a). The depth of gene detection was 1000X for tumor tissues and 10 000X for plasma. After palliative surgery, the patient commenced chemotherapy of pemetrexed combined with cisplatin. A CT scan taken after four cycles of chemotherapy revealed pulmonary metastasis and involvement of the right sacroiliac joint (Fig [1](#tca13023-fig-0001){ref-type="fig"}b) and the patient was evaluated with progressive disease (PD). A biopsy of the bone confirmed lung cancer metastasis by pathological examination. NGS of both metastatic bone tissue and plasma was conducted again with the same panel and still no mutation was detected (Fig [1](#tca13023-fig-0001){ref-type="fig"}a). In addition, immunohistochemistry (IHC) of the bone metastatic tissue showed PD‐L1 expression (SP142, Roche, Basel, Switzerland) in 65% of tumor cells (Fig [1](#tca13023-fig-0001){ref-type="fig"}b) and as a result chemotherapy was ceased and nivolumab administered. After three cycles of nivolumab treatment (3 mg/kg every two weeks), the patient was evaluated via CT as immunity unconfirmed PD (iUPD) (Fig [2](#tca13023-fig-0002){ref-type="fig"}a). Nivolumab treatment was not suspended until the patient was evaluated as immunity confirmed PD (iCPD), with dramatically increasing metastasis after another three cycles of nivolumab (Fig [2](#tca13023-fig-0002){ref-type="fig"}a). NGS of the plasma was implemented again to explore the possible resistance mechanism and a new *EGFR* exon 21 L858R mutation was detected (Figs [1](#tca13023-fig-0001){ref-type="fig"}a, [2](#tca13023-fig-0002){ref-type="fig"}c). The treatment was altered to gefitinib (250mg, orally, once a day) and after a month, CT revealed a partial response (Fig [2](#tca13023-fig-0002){ref-type="fig"}a). However the patient experienced a rapid relapse and died of tumor progression two months later. The tumor biomarkers CEA, CA12‐5, and CA19‐9 accordingly presented dynamic changes, along with different treatments for this patient (Fig [2](#tca13023-fig-0002){ref-type="fig"}b).

![(**a**) The timeline of next generation sequencing (NGS) and the various treatments administered. (**b**) Hematoxylin and eosin (HE) stain and immunohistochemistry (IHC) of CK, CK7, CK5/6, and PD‐L1.](TCA-10-1256-g001){#tca13023-fig-0001}

![(**a**) Computed tomography (CT) images of the patient. Red arrows show diffusion metastasis of the lung. (**b**) The dynamic change of biomarkers with CA19‐9, CEA, and CA12‐5 after each treatment (![](TCA-10-1256-g003.jpg "image")) CA19‐9, (![](TCA-10-1256-g004.jpg "image")) CEA, and (![](TCA-10-1256-g005.jpg "image")) CA12‐5. (**c**) Mutation of *EGFR* exon 21 L858R detected by next generation sequencing.](TCA-10-1256-g002){#tca13023-fig-0002}

The patient signed and provided written informed consent for the use of his data in publication.

Discussion {#tca13023-sec-0003}
==========

Although PD‐1 inhibitors are becoming the hotspot of anti‐cancer treatment and research, data is relatively limited regarding drug resistance mechanisms. The tumor interferon signaling pathway and JAK1/2 mutations have been suggested as potential resistance mechanisms to PD‐1 inhibitors.[8](#tca13023-bib-0008){ref-type="ref"}, [9](#tca13023-bib-0009){ref-type="ref"} Herein, for the first time, we detected an *EGFR* exon 21 L858R mutation as a potential acquired resistance mechanism of nivolumab in an NSCLC patient that was treated with gefitinib.

Two meta‐analyses reported that ICIs are less effective in pretreated *EGFR* mutated lung cancer patients than in those with wild type *EGFR*, which is probably related to a lower tumor mutation burden[10](#tca13023-bib-0010){ref-type="ref"} and the uninflamed and immunosuppressive tumor microenvironment of the latter subgroup of patients.[11](#tca13023-bib-0011){ref-type="ref"} However *EGFR* mutation has never been reported as an acquired resistance mechanism of ICIs. In our case, the patient showed a poor response to nivolumab with PD‐L1 expression in over 50% of tumor cells (although the predictive nature of tumor PD‐L1 expression in PD‐L1 inhibitor application is supported by KEYNOTE‐010 and CheckMate 057 trials). A new *EGFR* mutation was detected after icPD, which strongly suggests that *EGFR* exon 21 L858R is an acquired resistance mutation of nivolumab. Furthermore, this patient\'s original driver gene status was confirmed twice as negative by NGS of both tissue and blood. The second panel was taken before nivolumab was administered and the *EGFR* exon 21 L858R was detected right after acquired resistance to nivolumab, which largely reduces the odds that the exon 21 L858R mutation was the result of other drugs in the serial therapy. There is also the possibility that a portion of the tumors driven by exon 21 L858R existed below measurable limits in the beginning but became detectable after serial treatments, with the increase occurring during nivolumab application. In our opinion this supports the theory that an exon 21 L858R mutation is a resistance mechanism of nivolumab. However, more basic experiments and clinical research are warranted to prove this conclusion.

Few studies have investigated the effect of PD‐L1 expression on EGFR‐TKI efficacy and have reported controversial conclusions. Lin *et al.* found that when treating an *EGFR* mutant NSCLC patient with EGFR‐TKIs, PD‐L1‐positive patients had longer progression‐free and overall survival than PD‐L1 negative patients.[12](#tca13023-bib-0012){ref-type="ref"} However, several other studies drew the opposite conclusion.[13](#tca13023-bib-0013){ref-type="ref"}, [14](#tca13023-bib-0014){ref-type="ref"}, [15](#tca13023-bib-0015){ref-type="ref"} The patient in our report experienced a rapid relapse after gefitinib treatment and thus exhibited significantly short progression‐free and overall survival. More preclinical and clinical research is warranted to elucidate the underlying biology mechanism and other appropriate predictive biomarkers are required when treating patients with both PD‐L1 overexpression and *EGFR* mutations.

In conclusion, our results suggest that *EGFR* exon 21 L858R is an acquired resistance mechanism of nivolumab. Current information concerning cross‐talk between *EGFR* signaling pathways and PD‐1/PD‐L1 remains complicated and contentious, thus no consensus has been established regarding the optimal treatment approach for *EGFR* mutant/PD‐L1 positive NSCLC patients. *EGFR* exon 21 L858R mutant NSCLC patients may be less responsive to nivolumab. Gene detection should be conducted to identify the accurate resistance mechanism to provide precision treatment for patients.
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